TG Therapeutics, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-92.3% vs price
Base Case (Median)
-73.7% vs price
Bull Case (75th pct.)
1.2% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $1.94 | -96.1% | High (40%) |
| PE Comparable | $60.98 | 23.7% | Medium (25%) |
| Growth Trajectory DCF | $211.64 | 329.5% | Medium (20%) |
| Graham Number | $16.64 | -66.2% | Medium (40%) |
| EV/EBITDA | $9.31 | -81.1% | Medium (20%) |
| Earnings Power Value | $-27.50 | -155.8% | Medium (50%) |
Based on 6 out of 8 methods, TGTX appears fairly valued at the current price of $49.28. The base case fair value of $12.97 implies 73.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.